Why did the Novo Nordisk stock fall by more than 50% in 2025?

Three factors hit simultaneously: First, Eli Lilly with Zepbound (tirzepatide) took the clinical lead in the GLP-1 market. Second, the US government threatened pricing pressure on GLP-1 drugs through Medicare/Medicaid negotiations. Third, key markets (Brazil, Canada, China) saw semaglutide patents expire, enabling compounding competition. The result was the worst stock crash for Novo Nordisk in over 30 years — minus 54% from the peak.

What is the Wegovy pill and why does it matter?

The Wegovy pill (oral semaglutide in a higher dose, also known as Rybelsus at higher dosing) is the world's first oral GLP-1 medication for weight loss. FDA approval came in December 2025. In clinical trials, the pill achieved 16.6% weight loss — beating Eli Lilly's oral GLP-1 (orforglipron) at 12.4%. That is a direct competitive advantage and could massively expand the GLP-1 market: millions of patients who cannot tolerate injections could now be addressed.

What is the current PE ratio of Novo Nordisk and is it cheap?

Novo Nordisk's PE ratio following the price crash stands at around 11.5x (forward PE). The historical median is 30x. That means the stock is currently trading at a roughly 60% discount to its historical average valuation. That is objectively cheap — provided growth continues. The question is whether the market will permanently price in higher structural risks (patent expiry, competition).

Does Novo Nordisk pay a dividend and what is the history?

Yes. Novo Nordisk has paid and gradually increased its dividend for 8 consecutive years. The ROE (Return on Equity) stands at 53% — exceptionally high for a pharmaceutical company — which underscores the quality of the business. The current dividend yield is modest (below 2%), as the focus is on growth investments. As a dividend investor, NVO is not a classic high-yield name but a quality growth-dividend hybrid.

Novo Nordisk Analysis 2026: −50% Crash

2025 was Novo Nordisk’s worst year in over three decades. The stock fell minus 54% from its peak — and is now trading at a PE of 11.5x, against a historical median of 30x. At the same time, the company received FDA approval in December 2025 for the Wegovy pill — the world’s first oral GLP-1 weight-loss medication. A schizophrenic situation.

This is Pharma #01 in my new series. I am looking at NVO systematically: what went wrong in 2025, what the Wegovy pill changes, how the valuation compares historically, and what Q1 2026 earnings on May 6 must deliver.

−54%Crash From Peak (2025)

11.5xForward PE (vs. 30x median)

16.6%Wegovy Pill Weight Loss

53%ROE (Return on Equity)

1. The 2025 Worst Case — Three Factors Hit Simultaneously

The 54% price decline was not one event, but the convergence of three negative factors in 2025:

Factor 1: Eli Lilly Takes the GLP-1 Crown

Eli Lilly’s Zepbound (tirzepatide) outperformed Wegovy (semaglutide) in clinical head-to-head data on both weight loss and cardiovascular outcomes. That shifted the market’s narrative from “Novo Nordisk dominates GLP-1” to “Eli Lilly is taking over.” Investor confidence cracked.

Factor 2: Compounding Threat + Price Pressure

Patent expirations in key markets (Brazil, Canada, China) opened the door for compounding pharmacies offering cheaper semaglutide alternatives. Simultaneously, US government negotiations with Medicare/Medicaid created pricing pressure fears. Both factors compressed near-term revenue expectations significantly.

Factor 3: Valuation De-Rating from 40x to 11x

Growth momentum slows → the premium valuation compresses. A company that was priced at 40x earnings because of explosive growth gets de-rated to 11x when growth slows and competition intensifies. The math is brutal: even if earnings stay flat, multiple compression alone accounts for most of the price decline.

2. Wegovy Pill — The Counter-Catalyst

In December 2025, the FDA approved oral semaglutide in a higher-dose formulation for weight management — the world’s first oral GLP-1 medication for obesity.

Why does this matter?

Clinical efficacy: 16.6% body weight reduction in trials — beating Eli Lilly’s oral GLP-1 (orforglipron) at 12.4%
Market expansion: Millions of patients who avoid or cannot tolerate injections can now be addressed
Competitive moat: Novo Nordisk has years of experience with oral semaglutide manufacturing (Rybelsus for diabetes), giving it a production head start

Key Insight: The Wegovy pill does not just defend market share — it potentially opens a whole new addressable market. Analysts estimate the oral GLP-1 market alone could reach $50B+ by 2030. Novo Nordisk is first-mover with a superior efficacy profile.

3. Valuation: PE 11.5x vs. Historical Median 30x

The valuation picture is objectively striking:

Forward PE today: ~11.5x — at the crash low
Historical 10-year median PE: ~30x — when Novo Nordisk was a steady compounder
Discount: ~62% below the historical average

Is this justified? Two scenarios:

Bear case: Eli Lilly permanently dominates, compounding erodes margins, US pricing reform materializes → PE re-rates to 15–18x as a mature pharma with lower growth. Even at 15x, current prices are roughly fair.

Bull case: Wegovy pill opens a new market, GLP-1 global demand doubles, Novo Nordisk regains co-leadership → PE re-rates back toward 25–30x over 3–5 years. That implies 2–3x from current levels.

The market is pricing the bear case. The Wegovy pill data argues for the bull case. The question is: which scenario do you believe over a 3–5 year horizon?

4. Quality Indicators: ROE 53% and 8-Year Dividend Streak

Even in a down year, Novo Nordisk’s quality metrics remain exceptional:

ROE 53%: Among the highest in global pharma. This reflects pricing power, patent-protected products, and efficient capital allocation. Only companies with genuine moats sustain ROE above 40%.
8-year dividend streak: Novo Nordisk has increased its dividend every year for 8 consecutive years — through market cycles, pipeline setbacks, and now the 2025 crash.
Net cash position: No significant debt concerns — the company funds R&D from cash flow, not debt.

Context: As a dividend investor, NVO is not a high-yield play (current yield below 2%). It is a quality compounder with a long dividend growth track record trading at a distressed valuation. The thesis is total return: capital appreciation as the PE normalizes, plus growing dividends.

5. Q1 2026 Preview — May 6 Earnings

Novo Nordisk reports Q1 2026 on May 6, 2026. Key data points to watch:

Wegovy volume growth: How fast is the injectable version growing, and are there early read-throughs on the pill launch?
US pricing commentary: Has the Medicare/Medicaid pricing pressure materialized? What is the realized price per unit vs. expectations?
Ozempic (diabetes) volume: Stable base business — any supply disruption or demand softening would be a warning.
2026 guidance: Does management maintain or revise its full-year outlook? Guidance cut = negative; guidance hold or raise = stabilization signal.

6. Decision Framework — Buy, Hold or Avoid?

My Framework (April 2026):

BUY IF: You have a 3–5 year horizon, believe GLP-1 market grows faster than bears expect, and can tolerate further near-term volatility
HOLD IF: Already positioned at higher prices — thesis intact (Wegovy pill, quality business, PE compressed). Add on weakness.
AVOID IF: You need near-term catalysts, cannot stomach -30% more downside scenarios, or believe Eli Lilly dominates permanently and PE compresses further to 8–10x.

Key Risks: US Medicare negotiation outcomes (could structurally lower NVO revenue per unit). Orforglipron (Eli Lilly oral GLP-1) outperforming Wegovy pill in real-world data. Pipeline setbacks in CagriSema or other next-generation candidates. A broader pharma sector de-rating due to regulatory risk.

The series continues with Pharma #02 (Bayer) and Pharma #03 (Pfizer) — both at distressed valuations with different risk profiles. Novo Nordisk stays in my watchlist with a small initial position building thesis.

Disclaimer: This article is for informational and educational purposes only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All information provided without guarantee. Act on your own responsibility.

Novo Nordisk Crashed −50% — Buy the Dip or Yield Trap?